Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 Trial

Liver Cancer 2026 Open access

Read full text
Authors: Stephen Lam Chan, Ahmed Omar Kaseb, Laura Alexander, Xianzhang Meng, Kristin Ryan, Wei Shi, Arndt Vogel
DOI: 10.1159/000551156
Cited by: 1
References: 24

Abstract

Introduction: The CARES-310 randomized, open-label, international phase 3 trial reported improved overall survival and progression-free survival with camrelizumab-rivoceranib compared with sorafenib in adults with unresectable hepatocellular carcinoma (uHCC). Methods: We performed a post hoc analysis of data from CARES-310 to evaluate patient-reported outcomes (PROs), survival, and safety in adults

Fields of Study & Subjects

Hepatocellular Carcinoma Treatment and Prognosis Cancer Immunotherapy and Biomarkers Cholangiocarcinoma and Gallbladder Cancer Studies

Publication details

Journal / source
Liver Cancer
Publisher
S. Karger AG
Pages
1–15
Publication date
23 February 2026
Language
EN